ArticleFrontiers in pharmacology2026
Voriconazole-associated adverse drug reactions in Chinese patients: incidence, clinical features and the predictive value of ALBI score for hepatotoxicity.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the incidence, types, and risk factors of adverse drug reactions (ADRs) associated with voriconazole (VRC). Methods: A prospective observational study was conducted at the First Hospital of Changsha from March 1, 2024, to December 31, 2025. Multivariate logistic regression analyses and receiver operating characteristic (ROC) curve analysis were performed to identify risk factors of ADRs. Results: A total of 370 patients were included in the analysis. ADRs occurred in 70 patients (18.9%), while 300 patients (81.1%) experienced no ADRs. The most common ADRs were hepatotoxicity (39/370, 10.5%), neurological disorders (20/370, 5.4%), and visual symptoms (18/370, 4.9%). Most ADRs developed within 4-7 days after treatment initiation (53.6%). Notably, 59 patients (84.3%) discontinued VRC due to ADRs. Among patients with hepatotoxicity, the median trough concentration ( Conclusion: Early monitoring of VRC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.